Table 3.
Phase II/III trials of anti-epidermal growth factor receptor agents for advanced gastric cancer and gastro-esophageal junction cancer
| Trial | Phase | Setting | Regimen | Patients (n) | RR | OS (mo) | TTP (mo) |
| FOLCETUX[187], 2007 | II | 1st line | FOLFIRI + Cet | 38 | 44.1% | 16.0 | 8.0 |
| NCT00477711[188], 2008 | II | 1st line | CX + Cet | 54 | 48.1% | - | 5.23 |
| DOCETUX[95], 2009 | II | 1st line | C + TXT + Cet | 72 | 41.2% | 9.0 | 5.0 |
| AIO[93], 2010 | II | 1st line | FUFOX + Cet | 52 | 65.0% | 9.5 | 7.6 |
| NCT01123811[94], 2011 | II | 1st line | FOLFIRI + Cet | 49 | 46.0% | 16.5 | 90.0 |
| NCT00398398[189], 2011 | II | 1st line | XELOX + Cet | 44 | 52.3% | 11.8 | 6.5 |
| NCT00517829[96], 2013 | II | 1st line | DOCOX | 75 | 26.5% | 8.5 | - |
| DOCOX + Cet | 75 | 38.0% | 9.4 | - | |||
| EXPAND[97], 2013 | III | 1st line | CX + Cet | 455 | 29.0% | 9.4 | 4.4 |
| CX | 449 | 30.0% | 10.7 | 5.6 | |||
| REAL-III[103], 2013 | II-III | 1st line | EOX + P | 278 | 42.0% | 8.8 | 6.0 |
| EOX | 275 | 46.0% | 11.3 | 7.4 | |||
| NCT00113581[107], 2008 | I | 1st line | ECX + M | 21 | 65.0% | - | 5.2 |
| MATRIX[190], 2010 | II | 1st line | ECX + M | 35 | 58.0% | 12.2 | 7.1 |
| ECX | 31.0% | 9.4 | 4.8 | ||||
| NCT01813253[111], 2011 | II | 2nd line | Iri | 82 | 18.4% | 7.5% | 85 d |
| Iri + N | 10.3% | 9.7% | 73 d |
Cet: Cetuximab; C: Cisplatin; TXT: Docetaxel; X: Capecitabine; E: Epirubicin; O: Oxaliplatin; P: Panituimumab; E: Epirubicin; Iri: Irinotecan; M: Matuzumab; N: Nimotuzumab; FOLFIRI: 5 fluorouracil plus folinic acid plus irinotecan; FUFOX: 5 fluorouracil plus oxaliplatin; DOCOX: Docetaxel plus oxaliplatin; XELOX: Capecitabine plus oxaliplatin; RR: Response rate; OS: Overall survival; TTP: Time to progression.